Structural Heart Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Structural Heart Devices Market Report is Segmented by Product (Heart Valve Devices, Occluders and Delivery Systems, Annuloplasty Rings and Other Products), Procedure (Replacement Procedures and Repair Procedures), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD Million) for the Above Segments.

Structural Heart Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Structural Heart Devices Market Size

Global Structural Heart Devices Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 13.81 Billion
Market Size (2030) USD 21.48 Billion
CAGR (2025 - 2030) 9.24 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Global Structural Heart Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Structural Heart Devices Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Global Structural Heart Devices Market Analysis

The Global Structural Heart Devices Market size is estimated at USD 13.81 billion in 2025, and is expected to reach USD 21.48 billion by 2030, at a CAGR of 9.24% during the forecast period (2025-2030).

Structural heart devices are medical tools designed to diagnose and treat structural problems in the heart. They address both congenital and acquired conditions affecting the heart's valves, walls, chambers, or vessels. The market for these devices is growing significantly due to the global increase in cardiovascular diseases, supportive reimbursement policies, and a rising preference for minimally invasive procedures.

The primary catalyst for the growth of the market is the increasing prevalence of heart diseases, particularly structural heart conditions such as valvular heart disease, congenital heart defects, and atrial septal defects driven by factors such as aging populations, lifestyle-related diseases, unhealthy diets, and genetic factors. For instance, according to the data published by the Centers for Disease Control and Prevention in May 2024, congenital heart defects (CHDs) affect nearly 1% of or about 40,000 births per year in the United States. According to the same source, the prevalence of some heart defects, especially mild types, is increasing yearly. Infants with critical heart defects generally need surgery or other procedures in their first year of life. Thereby creating opportunities for structural devices such as heart valves, and annuloplasty rings. Therefore, the burden of heart diseases is expected to fuel market growth during the analysis period.

Furthermore, an increasing number of clinical trials highlighting the benefits of minimally invasive mitral valve repairs for patients with advanced heart failure are set to drive market growth during the forecast period. For example, in March 2023, Abbott shared important data for MitraClip, the top treatment for people with mitral regurgitation (MR) experiencing leaky valves. These findings highlighted the device's long-term benefits for heart failure patients. The five-year results from the landmark COAPT trial confirm that MitraClip is both safe and effective. It not only reduces hospitalizations but also improves survival for heart failure patients with severe secondary (or functional) MR—a condition historically hard to manage. Such successful clinical outcomes boost healthcare providers' confidence in these devices, improve patient outcomes and quality of life, and subsequently drive the growth of the structural heart devices market.

Moreover, market players are actively engaging in product launches, acquisitions, mergers, and investments, all of which are anticipated to bolster market growth. For example, in August 2024, Edwards made a strategic move by acquiring JenaValve Technology, a frontrunner in transcatheter treatments for aortic regurgitation (AR). JenaValve's Trilogy Heart Valve System, which is currently awaiting FDA approval projected for late 2025, is poised to be a game-changer. It stands as the inaugural therapy set to receive approval for treating symptomatic, severe AR—a condition that has been predominantly overlooked and is impacting an expanding patient demographic. This acquisition not only strengthens Edwards' foothold in the structural heart domain but also broadens its horizons to encompass heart failure management solutions. Such strategic maneuvers are set to propel the market's growth trajectory in the coming years.

Therefore, owing to the above-mentioned factors, such as increasing prevalence of heart diseases, the growing number of clinical trials, and strategic initiatives by key players such as acquisitions, the market studied is expected to grow over the forecast period. However, less accessibility to new technology in emerging markets and stringent approval process for structural heart devices are the factors that are anticipated to hinder market growth.

Global Structural Heart Devices Industry Overview

The market is competitive with the significant contribution of several public and private companies operating at the global level. Many companies are now exploring collaboration opportunities in many medical tourism destinations across the emerging markets of the world. Some of the top players include Abbott, Boston Scientific Corporation, Medtronic, Lepu Medical Technology(Beijing)Co.,Ltd., and Edwards Life Sciences Corporation, among others.

Global Structural Heart Devices Market Leaders

  1. Boston Scientific Corporation

  2. Edwards Lifesciences Corporation

  3. Medtronic

  4. Lepu Medical Technology(Beijing)Co.,Ltd.

  5. Abbott

  6. *Disclaimer: Major Players sorted in no particular order
Structural Heart Devices Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Global Structural Heart Devices Market News

  • August 2024: Boston Scientific Corporation secured the CE mark for its ACURATE Prime Aortic Valve System, marking the latest addition to its structural heart portfolio. This transcatheter aortic valve replacement (TAVR) technology enhances the clinical performance of the ACURATE neo2 platform, introducing an extra valve size to cater to patients with larger anatomies.
  • March 2024: Medtronic secured FDA approval for its Evolut FX+ transcatheter aortic valve replacement (TAVR) system, targeting symptomatic severe aortic stenosis. The new Evolut FX+ TAVR system not only upholds the performance advantages of its predecessor, the legacy Evolut TAVR platform, but is also engineered to enhance coronary access.

Global Structural Heart Devices Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Cardiovascular Diseases
    • 4.2.2 Technological Advancements in Structural Heart Devices
    • 4.2.3 Growth in Demand for Minimally Invasive Procedures
  • 4.3 Market Restraints
    • 4.3.1 Less Accessibility to New Technology in the Emerging Markets
    • 4.3.2 Stringent Approval Process for Structural Heart Devices
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product
    • 5.1.1 Heart Valve Devices
    • 5.1.2 Occluders & Delivery Systems
    • 5.1.3 Annuloplasty Rings
    • 5.1.4 Other Products
  • 5.2 By Procedure
    • 5.2.1 Replacement Procedures
    • 5.2.2 Repair Procedures
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 France
    • 5.3.2.2 Germany
    • 5.3.2.3 United Kingdom
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Biomerics
    • 6.1.3 Boston Scientific Corporation
    • 6.1.4 Braile Biomedica
    • 6.1.5 Edwards Lifesciences Corporation
    • 6.1.6 JenaValve
    • 6.1.7 Lepu Medical Technology(Beijing)Co.,Ltd.
    • 6.1.8 LivaNova PLC
    • 6.1.9 Medtronic
    • 6.1.10 Cryolife Inc.
    • 6.1.11 AtriCure, Inc.
    • 6.1.12 NuMed Inc.
    • 6.1.13 Venus Medtech (Hangzhou) Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Structural Heart Devices Industry Segmentation

As per the scope of the report, structural heart disease refers to defects in the heart that do not affect blood vessels. Many of these conditions are present at birth, but some can develop later in life due to infections or wear and tears. Advances in medicine have led to minimally invasive procedures, such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR), replacing traditional open-heart surgeries. The structural heart devices market is segmented by product, procedure, and geography. By product, the market is segmented into heart valve devices, occluders & delivery systems, annuloplasty rings, and other products. The other products segment includes surgical heart valves and transcatheter heart valves. By procedure, the market is segmented into replacement procedures and repair procedures. The report also covers the market size and forecasts for the Structural Heart Devices market in 17 countries across major regions. For each segment, the market sizing and forecasts have been done on the basis of value (USD). 

By Product Heart Valve Devices
Occluders & Delivery Systems
Annuloplasty Rings
Other Products
By Procedure Replacement Procedures
Repair Procedures
Geography North America United States
Canada
Mexico
Europe France
Germany
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Global Structural Heart Devices Market Research FAQs

How big is the Global Structural Heart Devices Market?

The Global Structural Heart Devices Market size is expected to reach USD 13.81 billion in 2025 and grow at a CAGR of 9.24% to reach USD 21.48 billion by 2030.

What is the current Global Structural Heart Devices Market size?

In 2025, the Global Structural Heart Devices Market size is expected to reach USD 13.81 billion.

Who are the key players in Global Structural Heart Devices Market?

Boston Scientific Corporation, Edwards Lifesciences Corporation, Medtronic, Lepu Medical Technology(Beijing)Co.,Ltd. and Abbott are the major companies operating in the Global Structural Heart Devices Market.

Which is the fastest growing region in Global Structural Heart Devices Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Structural Heart Devices Market?

In 2025, the North America accounts for the largest market share in Global Structural Heart Devices Market.

What years does this Global Structural Heart Devices Market cover, and what was the market size in 2024?

In 2024, the Global Structural Heart Devices Market size was estimated at USD 12.53 billion. The report covers the Global Structural Heart Devices Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Structural Heart Devices Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.